Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Annala Shirley

Nurse Practitioner Tyler, TX Nurse Practitioner

NPI 1215468129 CMS profile 10849722

721 Clinic Dr, Ste A, Tyler, TX 75701

Open in the dashboard

General payments

$5,707

220 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Annala Shirley of Tyler, TX is reported in the CMS Open Payments database as having received $5,707 across 220 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $436 11
2024 General $764 22
2023 General $1,752 68
2022 General $1,796 76
2021 General $959 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Annala Shirley
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Annala Shirley were reported at $436. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Annala Shirley Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $959 $135 $40–$426 $132
2022 $1,796 $152 $48–$470 $149
2023 $1,752 $166 $54–$529 $160
2024 $764 $173 $55–$556 $164
2025 $436 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Myriad Genetic Laboratories, Inc. $452 10 payments
  2. Novartis Pharmaceuticals Corporation $392 24 payments
  3. Janssen Biotech, Inc. $379 12 payments
  4. Lilly USA, LLC $379 10 payments
  5. Astellas Pharma US Inc $356 9 payments
  6. AbbVie, Inc. $266 12 payments
  7. Janssen Scientific Affairs, LLC $265 2 payments
  8. Pharmacyclics LLC, An AbbVie Company $254 9 payments
  9. Pfizer Inc. $239 13 payments
  10. Regeneron Healthcare Solutions, Inc. $198 10 payments
  11. Other $2,527 109 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,638 208 payments
  2. Education $1,069 12 payments
Products named General payments · program years 2021–2025
  1. myRisk $423 8 payments
  2. IMBRUVICA $343 13 payments
  3. EPKINLY $275 14 payments
  4. STELARA $265 2 payments
  5. REMICADE $265 2 payments
  6. TREMFYA $265 2 payments
  7. LIBTAYO $198 10 payments
  8. DARZALEX $163 4 payments
  9. Tavalisse $135 7 payments
  10. MONJUVI $133 7 payments
  11. Other $4,323 215 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$254,264

Of which drugs: $248,184

Medicare patients

98

Average age 74

Services billed

12,328

71 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Osteoporosis 44%
Ischemic heart disease 38%
COPD 32%
Diabetes 31%
Chronic kidney disease 31%
Cancer 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 26 1,620 $34,819

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BRIUMVI
  • TG Therapeutics, Inc. $90
$90 — —
TREMFYA
  • Janssen Scientific Affairs, LLC $88
$88 — —
STELARA
  • Janssen Scientific Affairs, LLC $88
$88 — —
REMICADE
  • Janssen Scientific Affairs, LLC $88
$88 — —
EPKINLY
  • AbbVie, Inc. $49
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record